Image Guided Procedures and Response Assessment It is Time to Move from Anatomic to Physiologic Imaging

Wayne L Monsky*
Department of Radiology, University of Washington Medical Center, 1959 Pacific Ave NE Seattle, WA 98195, USA

Minimally invasive image guided procedures are commonplace in nearly all areas of medicine. This is particularly true for the management of malignancies where initial diagnosis usually involves image-guided biopsy and treatment may involve image guided locoregional therapy such as tumor ablation or Transarterial Chemoembolization (TACE) [1-3]. Currently, the intra-procedural guidance and subsequent follow up for most of these procedures is based on gross anatomic visualization with CT, MRI, Ultrasound, and Fluoroscopy. The most important endpoint in cancer treatment is overall survival. Nonetheless, tumor response and time to progression are commonly used, imaging based, surrogate endpoints for assessment of efficacy. Ideally image based guidance and assessment of treatment response would evaluate the early mechanism of action of therapeutic and not only downstream resulting tumor shrinkage. Usual contrast enhanced imaging provides relatively general semi-quantitative assessment of perfusion and perhaps tissue viability. However, except for invasive angiography, it is currently not practical to perform real time enhanced or physiologic imaging during a procedure. A number of emerging functional, physiologic and molecular imaging approaches offer the promise of improved intra-procedural guidance and meaningful assessment of the actual mechanism of action of locoregional and targeted therapies. Furthermore, novel fusion/navigation approaches allow real time fusion of functional/physiological imaging with ultrasound or fluoroscopy for intra-procedural guidance [4]. These approaches may optimize tumor specific image guided interventions and help advance proteomics, targeted therapy and personalized medicine, were tumor cell protein expression is targeted or used to guide treatment [5]. Furthermore, they may better guide biopsies, increasing yield and reducing sample error. This has been a focus of a number of NIH/NCI initiatives including the Cancer Imaging Program (CIP) and Image Response Assessment Team (IRAT).

Emerging enhanced dynamic physiologic imaging, such as Dynamic Contrast Enhanced (DCE) CT/MRI or Contrast Enhanced Ultrasound, is beginning to be incorporated into clinical care. DCE-MRI or CT allows determination of tissue blood flow, blood volume, vascular permeability and mean transit times through the intra- and extravascular spaces [6,7]. Diffusion Weighted MRI (DWI) provides imaging of free unrestricted water associated with tissue edema, fibrosis, necrosis and apoptosis allowing evaluation of tumor viability at the cellular level [8,9]. Blood oxygen level-dependent (BOLD) magnetic resonance imaging (MRI) has been utilized as a sensitive and non-invasive tool to monitor the oxygenation state and blood perfusion of tissue [10]. A number of radio nuclides allow physiologic and molecular imaging. (18)F Fluorodeoxy Glucose positron emission tomography (FDG-PET) is part of standard imaging evaluation for a large number of neoplasms since metabolically active tumor cells have increased glucose uptake [11]. Thymidine analog 3'-deoxy-3'-18F-fluorothymidine (18F-FLT), is a new radiopharmaceutical for clinical PET that specifically visualizes proliferating tissue which permits estimation of tumor thymidine kinase-1 expression, and thus, cell proliferation [12]. Emerging PET imaging of hypoxia, with agents such as 18F Fluoromisonidazole (FMISO), has great potential for assessing tumor response, when the mechanism of action is reduction of blood flow/ischemia as with anti-angiogenic therapies and TACE [13]. These modalities can also be applied to image guided biopsies and percutaneous tumor ablation, to guide needle placement into viable tumor tissue, which at times may not be conspicuous, particularly with non-enhanced imaging [14]. However, it is not currently practical to perform procedures under PET guidance or during actual contrast enhancement with CT or MRI.

Emerging technologies allow fusion of images from PET or DCE MRI/CT with real time ultrasound to guide the biopsy needle or treatment to viable FDG avid or enhancing tumor [15]. Recently emerging cone beam CT angiography systems also allow real time multi-planar fusion of angiography with any DICOM (Digital Imaging and Communications in Medicine) imaging data, for guidance during fluoroscopic/angiographic procedures such as biopsies, TACE and Tumor Ablation [16]. Ultrasound contrast agents, consisting of a gas core encapsulated by a shell of lipid monolayer or cross-linked albumin [17], may also be used for real time guidance depicting tumor vascularity sensitively and accurately [18,19,20]. To date, no ultrasound contrast agents have received approval from the FDA for radiological applications in the USA and only two are approved for cardiac left ventricular opacification. Kono et al. demonstrated residual tumor blood flow on CEUS performed at 2 or more days after transarterial chemoembolization may be predictive of tumor outcome that currently requires 3 months to be reliably detected by computed tomography and/or magnetic resonance imaging [21].

Transarterial Chemoembolization (TACE) is used for a number of intrahepatic primary and metastatic malignancies and has been shown to improve survival in patients with Hepatocellular Carcinoma [22,23]. TACE efficacy is attributable to direct embolization of the tumor vasculature and infusion of high dose localized chemotherapy resulting in ischemic as well as cytotoxic injury. The sequence of tumor response involves devascularization, microenvironmental changes and tumor necrosis with later resultant reduction in tumor diameter. The reduction in overall tumor size may take at least a month to be seen on anatomic imaging, while devascularization and reduced perfusion, occurs immediately. Conventional anatomic imaging endpoints including Response Criteria in Solid Tumors (RECIST) [24] and World...
Health Organization (WHO) Criteria [25], in which single long axis or bi-dimensional linear measurements are made across the tumor, are likely not adequate for assessment following locoregional therapy [26,27]. The delivery of the therapeutic, subsequent intratumoral distribution and ultimate efficacy is directly related to tumor perfusion, vascular permeability, and interstitial transit. Therefore, assessment of tumor physiology, using these advances in imaging, can help to gauge and optimize the procedure in real time.

When evaluating molecular targeted and locoregional therapy, recent imaging based response criteria has focused on measurements of viable enhancing tumor and non-enhancing tumor necrosis on CT or MRI as described in The European Association for the Study of the Liver (EASL) criteria and the Modified RECIST Assessment (mRECIST) [28]. However, evolving techniques in Dynamic Contrast Enhanced (DCE) MRI/CT and DWI MRI allow the determination of microvascular parameters such as perfusion and permeability and apoptosis, which may provide early physiologic assessment following locoregional therapy [8,9]. Furthermore, Whal et al. proposed a PET based Response Criteria in Solid Tumors (PERCIST) [29]. Metabolic volume and total lesion glycolysis, according to PERCIST, predicted survival better than RECIST following Yitrium 90 radioembolization locoregional therapy of colorectal metastases [30] as well as HCC response according to TACE [31].

Emerging physiologic imaging approaches should be utilized to optimize intraintrprocedural guidance and response assessment of targeted and locoregional therapies.

References